About the Authors
- Mark Pimentel
-
* E-mail: pimentelm@cshs.org
Affiliation GI Motility Program, Cedars-Sinai Medical Center, Los Angeles, California, United States of America
- Walter Morales
-
Affiliation GI Motility Program, Cedars-Sinai Medical Center, Los Angeles, California, United States of America
- Ali Rezaie
-
Affiliation GI Motility Program, Cedars-Sinai Medical Center, Los Angeles, California, United States of America
- Emily Marsh
-
Affiliation GI Motility Program, Cedars-Sinai Medical Center, Los Angeles, California, United States of America
- Anthony Lembo
-
Affiliation Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America
- James Mirocha
-
Affiliation Department of Biostatistics, Cedars-Sinai Medical Center, Los Angeles, California, United States of America
- Daniel A. Leffler
-
Affiliation Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America
- Zachary Marsh
-
Affiliation GI Motility Program, Cedars-Sinai Medical Center, Los Angeles, California, United States of America
- Stacy Weitsman
-
Affiliation GI Motility Program, Cedars-Sinai Medical Center, Los Angeles, California, United States of America
- Kathleen S. Chua
-
Affiliation GI Motility Program, Cedars-Sinai Medical Center, Los Angeles, California, United States of America
- Gillian M. Barlow
-
Affiliation GI Motility Program, Cedars-Sinai Medical Center, Los Angeles, California, United States of America
- Enoch Bortey
-
Affiliation Salix Pharmaceuticals, Inc., Raleigh, North Carolina, United States of America
- William Forbes
-
Affiliation Salix Pharmaceuticals, Inc., Raleigh, North Carolina, United States of America
- Allen Yu
-
Affiliation GI Motility Program, Cedars-Sinai Medical Center, Los Angeles, California, United States of America
- Christopher Chang
-
Affiliation GI Motility Program, Cedars-Sinai Medical Center, Los Angeles, California, United States of America
Competing Interests
The authors have read the journal's policy and the authors of this manuscript have the following competing interests: Cedars-Sinai has a licensing agreement with Salix Pharmaceuticals, Commonwealth Laboratories, and Synthetic Biologics, Inc. Dr. Mark Pimentel is a paid consultant for Salix Pharmaceuticals, Commonwealth Laboratories, Micropharma Inc. Naia Pharmaceuticals and Synthetic Biologics Inc. Dr. Mark Pimentel and Dr. Christopher Chang are on the advisory board for Salix Pharmaceuticals. Dr. Anthony Lembo is a consultant for Salix Pharmaceuticals and Ironwood Pharmaceuticals. The remaining authors have no competing interests to disclose. The authors thank the Cedars-Sinai Inflammatory Bowel Disease Program for providing the blood samples from patients with inflammatory bowel disease used in this study. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: MP CC AL DL. Performed the experiments: WM EM ZM AY SW. Analyzed the data: AR JM MP CC WM EM ZM AY SW. Contributed reagents/materials/analysis tools: WF EB. Wrote the paper: MP AR CC GB WF EB AL DL WM KSC. Recruited subjects: KSC AL. Designed the clinical trial from which the IBS samples were derived: WF EB. Assisted with troubleshooting experiments: SW GB.